Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects With Moderate to Severe Parkins ...
Idiopathic Parkinson's Disease
Drug: Istradefylline 20 mg or 40 mg
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.
Completed
30 Years
N/A
All
239
Phase 3
United States;Canada;Czechia;Germany;Israel;Italy;Poland;Serbia;Czech Republic